First-Line Combination Chemotherapy with Cisplatin, Etoposide and Ifosfamide for the Treatment of Disseminated Germ Cell Cancer: Re-Evaluation in the Granulocyte Colony-Stimulating Factor Era

Chemotherapy ◽  
2013 ◽  
Vol 59 (6) ◽  
pp. 441-446 ◽  
Author(s):  
Hajime Tanaka ◽  
Takeshi Yuasa ◽  
Yasuhisa Fujii ◽  
Mizuaki Sakura ◽  
Shinji Urakami ◽  
...  
Keyword(s):  
Germ Cell ◽  
Combination Chemotherapy ◽  
Cell Cancer ◽  
Germ Cell Cancer ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
First Line ◽  
Stimulating Factor

scholarly journals The effect of primary granulocyte-colony stimulating factor prophylaxis on incidence of febrile neutropenia in patients with testicular germ cell tumors.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17056-e17056
Author(s):  
Nikola Hapakova ◽  
Michal Chovanec ◽  
Katarina Rejlekova ◽  
Katarina Kalavska ◽  
Jana Obertova ◽  
...  
Keyword(s):  
Overall Survival ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Primary Prophylaxis ◽  
Testicular Germ Cell Tumors ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
First Line ◽  
Testicular Germ Cell ◽  
Stimulating Factor

e17056 Background: Testicular germ cell tumors (GCTs) represent only one percent of all solid tumors; however, they are the most common solid malignancy in men 15-35 years old. Febrile neutropenia (FN) is a grievous complication of chemotherapy, frequently occurring in GCT patients. The aim of this retrospective study was to assess the effect of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis on the incidence of FN in GCT patients. Methods: This study was conducted using the National Cancer Institute medical records database. Patients diagnosed with germ cell tumors treated with first line/adjuvant chemotherapy at the National Cancer Institute, Bratislava, Slovakia from January 2000 to December 2017 were eligible. Starting in January 2006, patients received G-CSF prophylaxis after every cycle of chemotherapy. Results: Out of 393 patients, 265 patients received primary G-CSF prophylaxis and 128 patients did not receive prophylaxis. The majority of patients (69.97%) were treated with bleomycin, etoposide and cisplatin chemotherapy. There were 61 deaths (15.5%) in our study population. 2- and 5-year OS of the study group was 86.8% and 83.1%, respectively. During the study period, 71 patients (18.1%) suffered FN events. Out of 128 patients who did not receive primary prophylaxis, 42 (32.8%) patients suffered FN, while only 29 (10.9%) patients with primary prophylaxis suffered FN ( P = 0.0000001). On subgroup analysis, FN incidence decreased in all groups with primary prophylaxis, except for patients with stage I GCT receiving adjuvant chemotherapy. Patients receiving G-CSF prophylaxis had significantly longer overall survival when compared to patients without prophylaxis. (HR = 0.44, 95% CI 0.26-0.75; P = 0.0009). Conclusions: Primary G-CSF prophylaxis was associated with significantly decreased FN incidence and longer overall survival in patients treated with first line chemotherapy and should be consider in all patients except stage I disease.

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer

2004 ◽  
Vol 131 (4) ◽  
pp. 255-260 ◽  
Author(s):  
J. Wierecky ◽  
C. Kollmannsberger ◽  
I. Boehlke ◽  
M. Kuczyk ◽  
J. Schleicher ◽  
...  
Keyword(s):  
Germ Cell ◽  
Cell Cancer ◽  
High Dose Chemotherapy ◽  
Germ Cell Cancer ◽  
High Dose ◽  
Secondary Leukemia ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document